

#### UnitedHealthcare<sup>®</sup> Community Plan Medical Policy

# Skin and Soft Tissue Substitutes (for Ohio Only)

Policy Number: CS153OH.B Effective Date: March 1, 2024

Instructions for Use

Table of Contents	Page
Application	1
Coverage Rationale	1
Applicable Codes	1
U.S. Food and Drug Administration	5
References	6
Policy History/Revision Information	6
Instructions for Use	7

#### **Related Policies**

- Breast Reconstruction (for Ohio Only)
- Prolotherapy and Platelet Rich Plasma Therapies
   (for Ohio Only)

#### Application

This Medical Policy only applies to the state of Ohio. Any requests for services that are stated as unproven or services for which there is a coverage or quantity limit will be evaluated for medical necessity using Ohio Administrative Code 5160-1-01.

#### **Coverage Rationale**

For skin substitutes coverage and payment policies, refer to the <u>Ohio Administrative Code, Rule 5160-4-12(E)</u>, <u>Immunizations</u>, <u>injections and infusions (including trigger-point injections)</u>, skin substitutes, and provider-administered pharmaceuticals: <u>Coverage of skin substitutes</u>.

Refer to the Medical Policy titled <u>Breast Reconstruction (for Ohio Only)</u> for information about coverage for skin and soft tissue substitutes used during post mastectomy breast reconstruction procedures.

#### **Applicable Codes**

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS Code	Description
A2001	InnovaMatrix AC, per sq cm
A2002	Mirragen Advanced Wound Matrix, per sq cm
A2004	XCelliStem, per sq cm
A2005	Microlyte Matrix, per sq cm
A2006	NovoSorb SynPath dermal matrix, per sq cm
A2007	Restrata, per sq cm

Skin and Soft Tissue Substitutes (for Ohio Only) UnitedHealthcare Community Plan Medical Policy

Proprietary Information of UnitedHealthcare. Copyright 2024 United HealthCare Services, Inc.

HCPCS Code	Description
A2008	TheraGenesis, per sq cm
A2009	Symphony, per sq cm
A2010	Apis, per sq cm
A2011	Supra SDRM, per sq cm
A2012	SUPRATHEL, per sq cm
A2013	Innovamatrix FS, per sq cm
A2014	Omeza Collagen Matrix, per 100 mg
A2015	Phoenix wound matrix, per sq cm
A2016	PermeaDerm B, per sq cm
A2017	PermeaDerm glove, each
A2018	PermeaDerm CW, per sq cm
A2019	Kerecis Omega3 MariGen Shield, per sq cm
A2021	NeoMatriX, per sq cm
A4100	Skin substitute, FDA-clear as a device, not otherwise specified
Q4100	Skin substitute, not otherwise specified
Q4110	PriMatrix, per sq cm
Q4111	GammaGraft, per sq cm
Q4112	Cymetra, injectable, 1 cc
Q4114	Integra flowable wound matrix, injectable, 1 cc
Q4115	AlloSkin, per sq cm
Q4117	HYALOMATRIX, per sq cm
Q4118	MatriStem micromatrix, 1 mg
Q4121	TheraSkin, per sq cm
Q4122	DermACELL, DermACELL AWM or DermACELL AWM Porous, per sq cm
Q4123	AlloSkin RT, per sq cm
Q4125	Arthroflex, per sq cm
Q4126	MemoDerm, DermaSpan, TranZgraft or InteguPly, per sq cm
Q4127	Talymed, per sq cm
Q4130	Strattice TM, per sq cm
Q4132	Grafix Core and GrafixPL Core, per sq cm
Q4133	Grafix PRIME, GrafixPL PRIME, Stravix and StravixPL, per sq cm
Q4134	HMatrix, per sq cm
Q4135	Mediskin, per sq cm
Q4136	Ez-derm, per square centimeter
Q4137	AmnioExcel, AmnioExcel Plus or BioDExcel, per sq cm
Q4138	BioDFence DryFlex, per sq cm
Q4139	AmnioMatrix or BioDMatrix, injectable, 1 cc
Q4140	BioDFence, per sq cm
Q4141	AlloSkin AC, per sq cm
Q4142	Xcm biologic tissue matrix, per sq cm
Q4143	Repriza, per sq cm
Q4145	EpiFix, injectable, 1 mg

HCPCS Code	Description
Q4146	Tensix, per sq cm
Q4147	Architect, Architect PX, or Architect FX, extracellular matrix, per sq cm
Q4148	Neox Cord 1K, Neox Cord RT, or Clarix Cord 1K, per sq cm
Q4149	Excellagen, 0.1 cc
Q4150	AlloWrap DS or dry, per sq cm
Q4151	AmnioBand or Guardian, per sq cm
Q4152	DermaPure, per sq cm
Q4153	Dermavest and Plurivest, per sq cm
Q4154	Biovance, per sq cm
Q4155	Neox Flo or Clarix Flo 1 mg
Q4156	Neox 100 or Clarix 100, per sq cm
Q4157	Revitalon, per sq cm
Q4158	Kerecis Omega3, per sq cm
Q4159	Affinity, per sq cm
Q4160	Nushield, per sq cm
Q4161	Bio-connekt wound matrix, per sq cm
Q4162	WoundEx Flow, BioSkin Flow, 0.5 cc
Q4163	WoundEx, BioSkin, per sq cm
Q4164	Helicoll, per sq cm
Q4165	Keramatrix or Kerasorb, per sq cm
Q4166	Cytal, per sq cm
Q4167	Truskin, per sq cm
Q4168	Amnioband, 1 mg
Q4169	Artacent wound, per sq cm
Q4170	Cygnus, per sq cm
Q4171	Interfyl, 1 mg
Q4173	Palingen or palingen xplus, per sq cm
Q4174	Palingen or promatrx, 0.36 mg per 0.25 cc
Q4175	Miroderm, per sq cm
Q4176	Neopatch, per sq cm
Q4177	Floweramnioflo, 0.1 cc
Q4178	Floweramniopatch, per sq cm
Q4179	Flowerderm, per sq cm
Q4180	Revita, per sq cm
Q4181	Amnio wound, per sq cm
Q4182	Transcyte, per sq cm
Q4183	Surgigraft, per sq cm
Q4184	Cellesta or Cellesta Duo, per sq cm
Q4185	Cellesta Flowable Amnion (25 mg per cc); per 0.5
Q4186	Epifix, per sq cm
Q4187	Epicord, per sq cm
Q4188	AmnioArmor, per sq cm

Proprietary Information of UnitedHealthcare. Copyright 2024 United HealthCare Services, Inc.

HCPCS Code	Description
Q4189	Artacent AC, 1 mg
Q4190	Artacent AC, per sq cm
Q4191	Restorigin, per sq cm
Q4192	Restorigin, 1 cc
Q4193	Coll-e-Derm, per sq cm
Q4194	Novachor, per sq cm
Q4195	PuraPly, per sq cm
Q4196	PuraPly AM, per sq cm
Q4197	PuraPly XT, per sq cm
Q4198	Genesis Amniotic Membrane, per sq cm
Q4199	Cygnus matrix, per sq cm
Q4200	SkinTE, per sq cm
Q4201	Matrion, per sq cm
Q4202	Keroxx (2.5 g/cc), 1 cc
Q4203	Derma-Gide, per sq cm
Q4204	XWRAP, per sq cm
Q4205	Membrane graft or membrane wrap, per sq cm
Q4206	Fluid Flow or Fluid GF, 1 cc
Q4208	Novafix, per sq cm
Q4209	SurGraft, per sq cm
Q4210	Axolotl Graft or Axolotl DualGraft, per sq cm
Q4211	Amnion Bio or AxoBioMembrane, per sq cm
Q4212	AlloGen, per cc
Q4213	Ascent, 0.5 mg
Q4214	Cellesta Cord, per sq cm
Q4215	Axolotl Ambient or Axolotl Cryo, 0.1 mg
Q4216	Artacent Cord, per sq cm
Q4217	WoundFix, BioWound, WoundFix Plus, BioWound Plus, WoundFix Xplus or BioWound Xplus, per sq cm
Q4218	SurgiCORD, per sq cm
Q4219	SurgiGRAFT-DUAL, per sq cm
Q4220	BellaCell HD or Surederm, per sq cm
Q4221	Amnio Wrap2, per sq cm
Q4222	ProgenaMatrix, per sq cm
Q4224	Human Health Factor 10 Amniotic Patch (HHF10-P), per sq cm
Q4225	AmnioBind, per sq cm
Q4226	MyOwn Skin, includes harvesting and preparation procedures, per sq cm
Q4227	Amniocore, per square centimeter
Q4231	Corplex p, per cc
Q4232	Corplex, per square centimeter
Q4235	Amniorepair or altiply, per square centimeter
Q4236	CarePATCH, per square centimeter
Q4244	Procenta, per 200 mg

Proprietary Information of UnitedHealthcare. Copyright 2024 United HealthCare Services, Inc.

HCPCS Code	Description
Q4246	Coretext or protext, per cc
Q4247	Amniotext patch, per square centimeter
Q4248	Dermacyte amniotic membrane allograft, per square centimeter
Q4249	AMNIPLY, for topical use only, per sq cm
Q4250	AmnioAmp-MP, per sq cm
Q4251	Vim, per sq cm
Q4252	Vedaje, per sq cm
Q4253	Zenith amniotic membrane, per sq cm
Q4254	Novafix DL, per sq cm
Q4255	REGUaRD, for topical use only, per sq cm
Q4256	MLG-Complete, per sq cm
Q4257	Relese, per sq cm
Q4258	Enverse, per sq cm
Q4259	Celera Dual Layer or Celera Dual Membrane, per sq cm
Q4260	Signature APatch, per sq cm
Q4261	TAG, per sq cm
Q4262	Dual layer impax membrane, per square centimeter
Q4263	Surgraft tl, per square centimeter
Q4264	Cocoon membrane, per square centimeter
Q4265	NeoStim TL, per sq cm
Q4266	NeoStim Membrane, per sq cm
Q4267	NeoStim DL, per sq cm
Q4268	SurGraft FT, per sq cm
Q4269	SurGraft XT, per sq cm
Q4270	Complete SL, per sq cm
Q4271	Complete FT, per sq cm
Q4272	Esano A, per sq cm
Q4273	Esano AAA, per sq cm
Q4274	Esano AC, per sq cm
Q4275	Esano ACA, per sq cm
Q4276	ORION, per sq cm
Q4277	WoundPlus membrane or E-Graft, per sq cm
Q4278	EPIEFFECT, per sq cm
Q4280	Xcell Amino Matrix, per sq cm
Q4281	Barrera SL or Barrera DL, per sq cm
Q4282	Cygnus Dual, per sq cm
Q4283	Biovance Tri-Layer or Biovance 3L, per sq cm
Q4284	DermaBind SL, per sq cm

## U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Depending on their function and purpose, skin substitutes are regulated by the FDA through one of the following regulatory pathways:

- Premarket Approval (PMA): Devices that support or sustain human life or have the potential to cause risk of illness or injury are approved through the PMA process. These devices require clinical data to support their claims for use. Refer to the following website (search by product or applicant name):
   <u>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm.</u>
- Premarket Clearance or 510(k) Process: Devices that are substantively equivalent to legally marketed predicate devices that do not require PMA can be marketed under this designation. Refer to the following website (search by product or applicant name): <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm</a>.
- FDA's Definition under the Code of Federal Regulations (CFR) of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) addressed in Public Health Service 361 (Title 21, CFR 1270 & 1271): This pathway is available for biological tissue derived from human sources considered to be "minimally manipulated". Products that reach the market through the HCT/P process do not require any testing to prove clinical safety or efficacy. However, the manufacturer must meet specific FDA regulations for the collection, processing, and selling of HCT/Ps. Human amniotic membrane and amniotic fluid are included in these regulations. Human-derived tissue considered to be more than minimally manipulated require FDA premarket approval or 510(k) clearance. Refer to the following website for more information: <a href="https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products">https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products</a>.
- Humanitarian Device Exemption (HDE): The regulatory pathway for products intended for diseases or conditions that affect small populations, or are rare. Refer to the following website for more information: <u>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfHDE/hde.cfm</u>. (Accessed August 24, 2022)

#### References

Ohio Administrative Code/5160/Chapter 5160-1-01. Medicaid medical necessity: definitions and principles. Available at: <u>https://codes.ohio.gov/ohio-administrative-code/rule-5160-1-01</u>. Accessed September 26, 2023.

Ohio Administrative Code/5160/Chapter 5160-4-12. Immunizations, injections and infusions (including trigger-point injections), skin substitutes, and provider-administered pharmaceuticals Available at: <u>https://codes.ohio.gov/ohio-administrative-code/rule-5160-4-12</u>. Accessed September 26, 2023.

## **Policy History/Revision Information**

Date	Summary of Changes
03/01/2024	<ul> <li>Coverage Rationale</li> <li>Replaced coverage guidelines with instruction to refer to the:         <ul> <li>Ohio Administrative Code, Rule 5160-4-12(E), Immunizations, injections, and infusions (including trigger-point injections), skin substitutes, and provider-administered pharmaceuticals: Coverage of skin substitutes for skin substitutes coverage and payment policies</li> <li>Medical Policy titled Breast Reconstruction (for Ohio Only) for information about coverage for skin and soft tissue substitutes used during post mastectomy breast reconstruction procedures</li> </ul> </li> </ul>
	<ul> <li>Applicable Codes</li> <li>Added HCPCS codes Q4272, Q4273, Q4274, Q4275, Q4276, Q4277, Q4278, Q4280, Q4281, Q4282, Q4283, and Q4284</li> <li>Removed HCPCS codes Q4229, Q4230, Q4233, Q4234, Q4237, Q4238, Q4239, Q4240, Q4241, Q4242, and Q4245</li> </ul>
	<ul> <li>Supporting Information</li> <li>Updated <i>References</i> section to reflect the most current information</li> <li>Removed <i>Definitions</i>, <i>Description of Services</i>, and <i>Clinical Evidence</i> sections</li> <li>Archived previous policy version CS153OH.A</li> </ul>

### **Instructions for Use**

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state (Ohio Administrative Code [OAC]) or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state (OAC) or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state (OAC) or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state (OAC) or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare uses InterQual<sup>®</sup> for the primary medical/surgical criteria, and the American Society of Addiction Medicine (ASAM) for substance use, in administering health benefits. If InterQual<sup>®</sup> does not have applicable criteria, UnitedHealthcare may also use UnitedHealthcare Medical Policies, Coverage Determination Guidelines, and/or Utilization Review Guidelines that have been approved by the Ohio Department for Medicaid Services. The UnitedHealthcare Medical Policies, Coverage Determination Guidelines, and Utilization Review Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.